Astellas maintains lead over Daiichi Sankyo with CHMP okay for XospataAstellas’ FLT3 inhibitor for acute myeloid leukaemia (AML) – Xospata – has been recommended for approval in Europe, Share XAstellas maintains lead over Daiichi Sankyo with CHMP okay for Xospatahttps://pharmaphorum.com/news/astellas-maintains-lead-over-daiichi-sankyo-with-aml-drug-xospata/
Astellas gets nod in Japan for roxadustat, ahead of GSK rivalAstellas has its first approval for roxadustat, getting a green light in Japan for the drug as a Share XAstellas gets nod in Japan for roxadustat, ahead of GSK rivalhttps://pharmaphorum.com/news/astellas-gets-nod-in-japan-for-roxadustat-ahead-of-gsk-rival/
Democrats unveil price plan targeting 250 big-spend drugsThe Democrat plan to reduce medicines prices in the US has been published, confirming the intention to allow Share XDemocrats unveil price plan targeting 250 big-spend drugshttps://pharmaphorum.com/news/democrats-unveil-price-plan-targeting-250-big-spend-drugs/
Novartis points to Zolgensma long-term benefits amid data scandalNovartis has new data in hand for spinal muscular atrophy (SMA) gene therapy Zolgensma that it hopes will Share XNovartis points to Zolgensma long-term benefits amid data scandalhttps://pharmaphorum.com/news/novartis-points-to-zolgensmas-long-term-benefits-amid-data-scandal/
Merck, Eisai get triple approvals for Keytruda/Lenvima combinationThe combination of Merck & Co’s Keytruda with targeted drug Lenvima has been approved for endometrial cancer in Share XMerck, Eisai get triple approvals for Keytruda/Lenvima combinationhttps://pharmaphorum.com/news/merck-eisai-get-triple-approvals-for-keytruda-lenvima-combination/
eLucid gets US patents for smart pill dispenser deviceHealth tech firm eLucid mHealth has been granted a pair of US patents for its recently-launched Pill Connect, Share XeLucid gets US patents for smart pill dispenser devicehttps://pharmaphorum.com/news/elucid-gets-us-patent-for-smart-pill-dispenser-device/
J&J filing aims Tremfya at crowded psoriatic arthritis marketJohnson & Johnson has filed its IL-23 inhibitor Tremfya for approval in psoriatic arthritis (PsA), its second indication, Share XJ&J filing aims Tremfya at crowded psoriatic arthritis markethttps://pharmaphorum.com/news/jj-filing-aims-tremfya-at-crowded-psoriatic-arthritis-market/
FDA starts quick review of Astellas/Seattle Genetics’ bladder cancer drugThe FDA has started a priority review of Seattle Genetics and Astellas’ antibody-drug conjugate enfortumab vedotin in bladder Share XFDA starts quick review of Astellas/Seattle Genetics’ bladder cancer drughttps://pharmaphorum.com/news/fda-starts-quick-review-of-astellas-seattle-genetics-bladder-cancer-drug/
Purdue presses ahead with bankruptcy filingAs expected, Purdue Pharma has formally filed for bankruptcy protection as it tries to resolve thousands of lawsuits Share XPurdue presses ahead with bankruptcy filinghttps://pharmaphorum.com/news/purdue-presses-ahead-with-bankruptcy-filing/
